Remembering Longtime Community Leader, Lee Herron

Remembering Longtime Community Leader, Lee Herron

Georgia Bio Members & Partners:
 
It is with a heavy heart that I share with you the sad news that Georgia has lost one of its long-time innovation and entrepreneurship champions with the passing of Dr. Lee Herron last Friday, July 12.



Lee was a dear friend, colleague, mentor, and irreplaceable leader within our community. He retired from Georgia Research Alliance (GRA) in spring 2024 after a 16-year career with the Alliance. Most recently, Lee led GRA’s agricultural technology programs including the Greater Yield initiative. He directed its award-winning venture development program for 15 years, which helped to launch 200+ university-based companies that attracted more than $2 billion in equity investment. A seasoned executive, Lee harnessed his 20 years of entrepreneurial experience to help startups develop sound business strategies. Prior to joining GRA, Lee managed the biosciences division of Georgia Tech’s Advanced Technology Development Center (ATDC), advising early-stage life science companies. Lee served in many community leadership capacities including on the boards of Georgia Bio, Southeast Life Sciences, the Global Center for Medical Innovation’s Industry Advisory Board, the Biolocity Oversight Committee and the NSF Center for Cell Manufacturing Technology’s Commercialization Advisory Board.

I am at a loss to even estimate the vast impact he has had on so many of us not only in a business capacity but also as a wise and caring leader whose warmth and humanity characterized every interaction with him. I encourage you to read the moving tributes from GRA here, and his protégé, Ashley Cornelison’s LinkedIn post here. For those that did not know Lee, these tributes help to paint the picture of a brilliant and kind man who will leave an indelible mark on many across our industry. 

On a personal note, Lee has been a mentor, sounding board, and friend throughout my 18 years at Georgia Bio. A regular volunteer with Georgia Bio for over 2 decades, Lee would provide his feedback on nominees for our annual awards without hesitation and with his trademark candor; he always jumped to help the organization build its network; and served in various leadership capacities including as chair for our Life Sciences Summit in 2017 (pictured). At the same time, he would remember to ask me about my daughter and remind me to take care of myself. Lee enjoyed and excelled at connecting with people, and his health challenges rarely slowed him down. In looking at my last texts with him from mid-May, he was still committing to providing feedback on our Golden Helix Award nominees and suggesting he introduce me to one of his industry colleagues. I am truly heartbroken. His honesty, humor, and guidance on a personal and professional level will be missed.
 
Lee was an early recipient of Georgia Bio’s highest honor, the Industry Growth Fellow Award in 2008. Georgia Bio will honor Lee and his legacy at this year’s Georgia Life Sciences Summit on October 22.
 
Please continue sending your thoughts and prayers for Lee’s wife Rita and the Herron family.

A memorial service will take place this Thursday, July 18. More here.
 
With heartfelt sympathy,


Maria
President & CEO
Georgia Bio

Georgia Life Sciences Weighs In on PBM and 340B Policy

October 5, 2026
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers’ Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system. The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients. The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly. Read Georgia Life Sciences’ full comments →

Georgia Life Sciences Joins National Coalition Calling for PAHPA Reauthorization

September 22, 2026
Georgia Life Sciences (GLS) has joined more than 80 organizations from across industry, academia, public health and the biosecurity community in calling on congressional leaders to fully reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of 2026. Led by the Johns Hopkins Center for Health Security, the coalition urged congressional leaders to advance a comprehensive reauthorization of PAHPA, the federal framework that supports the nation’s ability to prepare for and respond to public health emergencies and other health security threats. First enacted in 2006, PAHPA established and strengthened critical components of the nation’s health security infrastructure, including the Biomedical Advanced Research and Development Authority (BARDA). The law also supports public-private partnerships involved in the research, development, manufacturing and procurement of medical countermeasures, including vaccines, therapeutics and diagnostics. PAHPA’s authorization expired in 2023 and key provisions have since continued through short-term extensions. The coalition is calling for a comprehensive reauthorization that provides greater stability and ensures the nation’s preparedness infrastructure can continue adapting to emerging biological, infectious disease and other health security threats. For the life sciences industry, these programs are particularly important. Partnerships between government and industry can help move promising technologies from research through development and manufacturing while maintaining capabilities needed to respond quickly during an emergency. The Biotechnology Innovation Organization (BIO), also a signatory to the letter, has identified several priorities for reauthorization, including continued authorization of BARDA, the Strategic National Stockpile, Project BioShield and the Pandemic Influenza Program, as well as incentives supporting the development of medical countermeasures. Georgia Life Sciences is proud to join organizations across the country in supporting a strong and sustainable national framework for health security, preparedness and biomedical innovation. Read the coalition letter and view the full list of signatories.

Georgia Life Sciences Urges Protection of Patient Access as Georgia Implements Medicaid Changes

September 14, 2026
Georgia Life Sciences has submitted comments to the Georgia Department of Community Health (DCH) regarding the Georgia Pathways to Coverage program and implementation of new federal Medicaid requirements. As Georgia prepares for these changes, Georgia Life Sciences is urging state leaders to prioritize continuity of care and minimize unnecessary administrative barriers that could delay or disrupt access to medically necessary treatment . This is particularly important for Georgians living with serious, chronic, rare, and medically complex conditions who may rely on ongoing medications, diagnostics, therapies, medical technologies, specialty care, and coordinated treatment plans. Even temporary disruptions in coverage can interrupt care and create additional challenges for patients and families. In its comments, Georgia Life Sciences encouraged DCH to protect continuity of coverage during eligibility and redetermination processes, provide patients and caregivers with clear and timely information, minimize unnecessary administrative burdens, and establish appropriate safeguards when a coverage disruption could interrupt an established course of treatment. “As Georgia implements these new federal requirements, we want to ensure that patients remain at the center of the process,” said Maria Thacker Goethe, MPH, President & CEO of Georgia Life Sciences. “Administrative changes should not become barriers between patients and the care they need. Protecting continuity of care is particularly important for Georgians managing serious and complex health conditions.” Read Georgia Life Sciences’ full comments to DCH here.
MORE POSTS